A higher IFN-γ/IMS ratio was associated with a modest prognostic benefit after adjusting for sex, age, and TMB in breast invasive carcinoma (BRCA) (HR = 0.92; 95% CI: 0.82–0.98), cutaneous melanoma (SKCM) (HR = 0.89, 95% CI: 0.87–0.99), stomach adenocarcinoma (STAD) (HR = 0.86; 95% CI: 0.77–0.96), bladder urothelial carcinoma (BLCA) (HR = 0.93; 95% CI: 0.87–0.99) and cervical tumors (CESC) (HR = 0.85; 95% CI: 0.74–0.98). This evidence concerns the gene IFNG and cutaneous melanoma.